Browse > Article
http://dx.doi.org/10.11644/KIEP.EAER.2020.24.2.374

The Health Impact of, and access to, New Drugs in Korea  

Lichtenberg, Frank R. (Columbia University, National Bureau of Economic Research, and CESifo)
Publication Information
East Asian Economic Review / v.24, no.2, 2020 , pp. 127-164 More about this Journal
Abstract
We perform an econometric assessment of the role that pharmaceutical innovation-the introduction and use of new drugs-has played in improving the health of Koreans, by investigating whether diseases for which more new drugs were launched had larger subsequent increases in longevity and smaller subsequent increases in hospitalization. Drugs launched during 1993-2012 are estimated to have increased mean age at death from all diseases by 1.71 years between 1995 and 2015 and 1.09 years between 2005 and 2015. We also estimate that new drugs increased the five-year relative survival rate from all cancers combined by 23.2 percentage points-78.5% of the total increase-between 1993-1995 and 2011-2015, and that new drugs launched during 2008-2010 reduced the number of hospital days in 2017 by 13.0 million. If the drugs launched during 2003-2012 had had no effect on other medical expenditure in 2015, the cost per life-year gained would not have exceeded 6332 USD. Therefore, even if we ignore the effect of new drugs on hospital utilization, the drugs launched during 2003-2012 were very cost-effective, overall. When reduced hospital utilization is accounted for, the evidence indicates that, in the long run, pharmaceutical innovation was cost-saving as well as life-year saving.
Keywords
Longevity; Pharmaceutical; Innovation; Korea; Hospitalization; Cancer;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Aghion, P. and P. Howitt. 2005. Growth with Quality-Improving Innovations: An Integrated Framework. In Aghion, P. and S. N. Durlauf. (eds.) Handbook of Economic Growth. vol. 1, part A, Amsterdam: Elsevier. pp. 67-110.
2 Bertram, M. Y., Lauer, J. A., De Joncheere, K., Edejer, T., Hutubessy, R., Kieny, M. P. and S. R. Hill. 2016. "Cost-Effectiveness Thresholds: Pros and Cons," Bulletin World Health Organization, vol. 94, no. 12, pp. 925-930.   DOI
3 Bils, M. 2004. Measuring the Growth from Better and Better Goods. NBER Working Paper, no. 10606.
4 Bresnahan, T. F. and R. J. Gordon. 1996. The Economics of New Goods. Chicago: University of Chicago Press.
5 Dorsey, E. R., de Roulet, J., Thompson, J. P., Reminick, J. I., Thai, A. White-stellato, Z., Beck, C. A., George, B. P., and H. Moses III. 2010. "Financial Anatomy of Biomedical Research, 2003-2008," Journal of the American Medical Association, vol. 303, no. 2, pp. 137-143.   DOI
6 Grossman, G. M. and E. Helpman. 1991. Innovation and Growth in the Global Economy. Cambridge: MIT Press.
7 Hausman, J. 2001. "Mismeasured Variables in Econometric Analysis: Problems from the Right and Problems from the Left," Journal of Economic Perspectives, vol. 15, no. 4, pp. 57-67.   DOI
8 International Federation of Pharmaceutical Manufacturers & Associations. 2017. The Pharmaceutical Industry and Global Health: Facts and Figures 2017. (accessed January 21, 2020)
9 Jones, C. I. 1998. Introduction to Economic Growth. New York: W.W. Norton.
10 Jones, C. I. 2002. "Sources of U.S. Economic Growth in a World of Ideas," American Economic Review, vol. 92, no. 1, pp. 220-239.   DOI
11 Jovanovic, B. and Y. Yatsenko. 2012. "Investment in Vintage Capital," Journal of Economic Theory, vol. 147, no. 2, pp. 551-569.   DOI
12 Jung, K.-W., Won, Y.-J., King, H.-J., Lee, E. S. and The Community of Population-Based Regional Cancer Registries. 2018. "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015," Cancer Research and Treatment, vol. 50, no. 2, pp. 303-316.   DOI
13 Koc, C. 2004. "The Productivity of Health Care and Health Production Functions," Health Economics, vol. 13, no. 8, pp. 739-747.   DOI
14 Kolata, G. 2019. Surgery for Blocked Arteries Is Often Unwarranted, Researchers Find. New York Times, vol. 169, no. 58,514, Section A, p. 19. (Print November, 17, Online November, 16)
15 Lichtenberg, F. R. 2009. "Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence from Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003," Health Economics, vol. 18, no. 5, pp. 519-534.   DOI
16 Lichtenberg, F. R. 2014a. "Has Medical Innovation Reduced Cancer Mortality?" CESifo Economic Studies, vol. 60, no. 1, pp. 135-177.   DOI
17 Lichtenberg, F. R. 2014b. "The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in France, 2000-2009," Economics and Human Biology, vol. 13, pp. 107-127.   DOI
18 Lichtenberg, F. R. 2014c. "Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009," Health Policy and Technology, vol. 3, no. 1, pp. 36-58.   DOI
19 Lichtenberg, F. R. 2014d. "The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997-2010," Journal of Human Capital, vol. 8, no. 4, pp. 432-480.   DOI
20 Lichtenberg, F. R. 2018. "The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: a Two-Way Fixed-Effects Analysis," Forum for Health Economics & Policy, vol. 21, no. 2. (accessed January 21, 2020)
21 National Cancer Institute. 2012. Long-Term Trial Results Show No Mortality Benefit from Annual Prostate Cancer Screening. (accessed December 7, 2019)
22 National Cancer Institute. 2019. Enhancing Drug Discovery and Development. (accessed December 7, 2019)
23 National Institute for Health and Care Excellence. 2019. The Guidelines Manual: Assessing cost effectiveness. (accessed December 7, 2019)
24 Nordhaus, W. D. 2005. "Irving Fisher and The Contribution of Improved Longevity to Living Standards," American Journal of Economics and Sociology, vol. 64, no. 1, pp. 367-392.   DOI
25 Organisation for Economic Co-operation and Development (OECD). 2019a. OECD Health Statistics 2019 Definitions, Sources and Methods Hospital discharges by diagnostic categories. (accessed March 21, 2020)
26 Organisation for Economic Co-operation and Development (OECD). 2019b. International shortlist for hospital morbidity tabulation. (accessed March 21, 2020)
27 Organisation for Economic Co-operation and Development (OECD). 2019c. OECD Health Statistics database. (accessed December 7, 2019)
28 U.S. Department of Veterans Affairs, Health Economics Resource Center. 2019. Budget Impact Analysis. (accessed January 21, 2020)
29 Sampat, B. and F. R. Lichtenberg. 2011. "What are the Respective Roles of the Public and Private Sectors in Pharmaceutical Innovation?" Health Affairs, vol. 30, no. 2, pp. 332-339.   DOI
30 Statistics Korea. 2010. 2009 Life Tables for Korea. (accessed January 21, 2020)
31 World Health Organization (WHO). 2019. Cause of Death Query online database. (accessed January 21, 2020)
32 Yang, S., Khang, Y.- H., Harper, S., Davey Smith G., Leon, D. A. and J. Lynch. 2010. "Understanding the rapid increase in life expectancy in South Korea," American Journal of Public Health, vol. 100, no. 5, pp. 896-903.   DOI
33 Centre National Hospitalier d'Information sur le Medicament. 2019. Theriaque database. (accessed January 21, 2020)